Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.

Rousseau A, Karimi M, Michiels S, Roubaud G, Maldonado X, Supiot S, McDermott R, Flechon A, Tombal B, Ronchin P, Berthold D, Berdah JF, Kacso G, Gravis G, Calabro F, Tartas S, Muracciole X, Ribault H, Fizazi K, Foulon S

Open source

DOI: 10.1016/j.ejca.2025.116024
Published: 2025 Nov 17
Container: European journal of cancer (Oxford, England : 1990)
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ejca.2025.116024,
  title = {Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.},
  author = {Rousseau A and Karimi M and Michiels S and Roubaud G and Maldonado X and Supiot S and McDermott R and Flechon A and Tombal B and Ronchin P and Berthold D and Berdah JF and Kacso G and Gravis G and Calabro F and Tartas S and Muracciole X and Ribault H and Fizazi K and Foulon S},
  year = {2025},
  journal = {European journal of cancer (Oxford, England : 1990)},
  doi = {10.1016/j.ejca.2025.116024},
  url = {https://doi.org/10.1016/j.ejca.2025.116024}
}

RIS

TY  - JOUR
TI  - Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.
AU  - Rousseau A
AU  - Karimi M
AU  - Michiels S
AU  - Roubaud G
AU  - Maldonado X
AU  - Supiot S
AU  - McDermott R
AU  - Flechon A
AU  - Tombal B
AU  - Ronchin P
AU  - Berthold D
AU  - Berdah JF
AU  - Kacso G
AU  - Gravis G
AU  - Calabro F
AU  - Tartas S
AU  - Muracciole X
AU  - Ribault H
AU  - Fizazi K
AU  - Foulon S
PY  - 2025
JO  - European journal of cancer (Oxford, England : 1990)
DO  - 10.1016/j.ejca.2025.116024
UR  - https://doi.org/10.1016/j.ejca.2025.116024
ER  -

APA

A, R., M, K., S, M., G, R., X, M., S, S., R, M., A, F., B, T., P, R., D, B., JF, B., G, K., G, G., F, C., S, T., X, M., H, R., K, F., & S, F. (2025). Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trial.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2025.116024

Source records

pubmed · retrieved 2026-09-24T23:28:31.472Z